Alkermes’ Corporate Presentation to be Webcast at the NASDAQ OMX 27th Investor Program

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the NASDAQ OMX 27th Investor Program on Tuesday, December 6, 2011, at 1:15 p.m. GMT (8:15 a.m. ET) from the Chancery Court Hotel in London. The presentation may be accessed from the investor relations section on www.alkermes.com and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.



CONTACT:

Alkermes plc
Eva Stroynowski, +1-781-609-6823
Corporate Communications

KEYWORDS:   United Kingdom  United States  Europe  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Banking  Finance

MEDIA:

Logo
 Logo

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.